MondayMar 31, 2025 10:00 am

Natural Killer Cells That are Genetically Modified Show Potential in Cancer Immunotherapy

Under normal circumstances, natural killer cells in the body can detect and eliminate malignant cells. However, these NK cells can at times be unable to breach the defense mechanisms of tumors, rendering the killer cells unable to combat the growing cancer. A recent pre-clinical study suggests that natural killer cells can be tweaked in a bid to boost their ability to fight cancerous cells. This study’s findings appeared in the Nature Immunology journal and the work was a collaborative effort between several universities and companies. These included Pompeu Fabra University, Karolinska Institutet located in Sweden, a Germany-based company called Miltenyi…

Continue Reading

ThursdayMar 27, 2025 9:00 am

SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Expands Solar Portfolio with Two New Projects in Upstate New York

The Jordan Rd, Gainesville project will have a capacity of 7.2 MW DC, while the Glen Rd project will have a capacity of 4.3 MW DC. The projects are expected to provide electricity to approximately 1,350 homes. Both projects will operate under New York’s community solar model, allowing residents to benefit from solar energy without installing panels. Solar Simplified will manage customer-facing operations, ensuring smooth implementation and subscription management. These projects further enhance the company’s development pipeline that exceeds one gigawatt. Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner…

Continue Reading

WednesdayMar 26, 2025 9:45 am

D-Wave Quantum Inc. (NYSE: QBTS) Reports Strong Q4, 2024 Results with Increased Bookings and Cash Position

D-Wave’s 2024 bookings reached $23.9 million, a 128% increase from 2023, with Q4 bookings up 502% year-over-year. The company reported a cash position exceeding $300 million as of March 13, 2025. Significant technical and business milestones achieved in the past year include a quantum supremacy demonstration and the sale of an Advantage quantum computer to Julich Supercomputing Centre. New partnerships and customer projects were announced, spanning industries such as insurance, law enforcement, and agriculture. D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, reported financial performance for the fourth quarter and full-year 2024, highlighting…

Continue Reading

WednesdayMar 26, 2025 9:00 am

SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) CEO Richard Lu Discusses Company Mission, Near-Term Goals on Bell2Bell, Quick Charge Podcasts

As a vertically integrated company, SolarBank has a full-service solar integration and support offering, handling development, construction, and ownership, Lu said. The company’s current pipeline includes solar, battery storage, and EV charging projects, totaling over 1 gigawatt of capacity across Canada and the U.S. SolarBank is currently developing four large-scale battery energy storage systems – three in Ontario and one in New York. CEO Richard Lu explained why battery energy storage plays an essential role in the modern electricity grid, helping address renewable energy intermittencies and ensuring enhanced reliability of supply. The company currently owns approximately $180 million in assets…

Continue Reading

TuesdayMar 18, 2025 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) Demonstrates Quantum Supremacy on a Real-World Problem

D-Wave has shown quantum computational supremacy on a useful, real-world problem, a first in the industry, highlighting the potential of quantum computing for materials discovery and complex simulations beyond classical computational limits. A peer-reviewed paper published in Science validates that D-Wave’s annealing quantum computer solved a magnetic materials simulation problem that is beyond the capabilities of classical supercomputers. The simulation, which took minutes to solve on D-Wave’s system, would require nearly one million years and more electricity than the world’s annual consumption on a GPU-based supercomputer. The Advantage2 annealing quantum computer prototype was used to achieve this milestone and is…

Continue Reading

FridayMar 07, 2025 10:45 am

D-Wave Quantum Inc. (NYSE: QBTS), Staque Develop Hybrid Quantum Application to Optimize Autonomous Agriculture Vehicles

The companies expect the application to accelerate autonomy in agriculture, streamlining agricultural operations. The technology aims to enhance efficiency in large-scale farming by providing real-time optimization solutions. The initiative is part of a broader strategic partnership between D-Wave and Staque to accelerate commercial adoption of annealing quantum computing. D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, and the first supplier of production-grade quantum computers, and Staque, a leading consulting and development practice in AI, blockchain and quantum computing, collaborated to develop a hybrid-quantum system designed to optimize the movements of autonomous agricultural vehicles…

Continue Reading

WednesdayMar 05, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Pioneers Systemic Virotherapy with RTNova Platform

Calidi’s RTNova platform leverages engineered enveloped vaccinia viruses designed for systemic delivery. Calidi’s groundbreaking virotherapy holds “immense promise in revolutionizing the treatment landscape for cancer patients with advanced solid tumors,” says CEO. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of developing innovative immunotherapies for cancer treatment. Most recently, the company has captured the spotlight for the development of its proprietary systemic platform, RTNova (https://ibn.fm/Z4pM3). The platform represents a significant advancement in systemic virotherapy, particularly in the utilization of enveloped virotherapies to target metastatic tumors across the body. Antitumor virotherapy employs viruses that selectively infect and…

Continue Reading

Contact us: (512) 354-7000